International Breast Cancer Center IBCC (Barcelona)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Breast Imaging Unit at the International Breast Cancer Center (IBCC) and at the Teknon Medical Center in Barcelona.
Head of the International Breast Cancer Centre IBCC (Barcelona), Scientific Medical Director of the Institute of Oncology of Madrid (IOB) and co-founder of Medica Scientia Innovation Research (MedSIR)
Between April 2021 and December 2022, more than 100,000 women in Sweden were randomly assigned to either AI-assisted mammography screening or double reading, where two radiologists review each mammogram without the aid of AI. AI-assisted screening identified more women with significant cancers without a higher rate of false positives and also achieved a 12% reduction in the rate of interval cancers—those that appear between mammograms because they went unnoticed or are newly developed and more aggressive—compared to the double reading procedure. This is the first clinical trial of its kind, and its results are published in The Lancet.
For women diagnosed with early-stage breast cancer, the long-term risk of developing a second primary cancer is low, around 2–3 per cent higher than that of women in the general population. This is one of the conclusions of a study published by The BMJ, which analysed data from nearly half a million women diagnosed in England between 1993 and 2016 with early-stage invasive breast cancer who underwent surgery. During a follow-up period of up to 20 years, around 65,000 women developed a second primary cancer, but the absolute excess risk compared to the risks in the general population was small.
A standard chemotherapy drug injures surrounding noncancerous cells, which can awaken dormant cancer cells and promote cancer growth, according to a study published today in the journal PLOS Biology.